Reuptake

Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets

Retrieved on: 
Thursday, December 23, 2021
NDA, Conference, Medicine in China, New Drug Application, Patient, LY03005, Somnolence, Phase, Major depressive disorder, SNDRI, Reuptake, NCE, MDD, Hamilton Rating Scale for Depression, Safety, Pharmaceutical industry, New chemical entity

CHONGQING, China, Dec. 23, 2021 /PRNewswire/ --Luye Pharma Group today released the encouraging top-line results from a Phase II clinical trial of its new antidepressant, Ansofaxine Hydrochloride Extended-Release Tablets (LY03005), at the 19thNational Psychiatry Conference of the Chinese Medical Association.

Key Points: 
  • CHONGQING, China, Dec. 23, 2021 /PRNewswire/ --Luye Pharma Group today released the encouraging top-line results from a Phase II clinical trial of its new antidepressant, Ansofaxine Hydrochloride Extended-Release Tablets (LY03005), at the 19thNational Psychiatry Conference of the Chinese Medical Association.
  • In general, LY03005 demonstrated a comprehensive antidepressant efficacy as well as a good safety profile and tolerance based on the initial results of the Phase II clinical trial.
  • The drug has completed Phase I to Phase III clinical trials and is currently in the New Drug Application (NDA) phase in China.
  • In addition to China, LY03005 is also undergoing NDA phase in the U.S., and has completed Phase I clinical trials in Japan.